PHARMAC is seeking applications from people who have the appropriate knowledge, experience and networks within the Māori community to be appointed to the Consumer Advisory Committee (CAC). Due to our current Māori representatives completing their terms, there are two vacancies. Closes: 4 March 2016.
PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd (“Novartis”) involving filgrastim, used to reduce neutropenia and during mobilisation for...
Are you looking for your next career step as a Communications Manager? We are seeking an ambitious yet collaborative leader and team player, who is outwardly focused and thrives in a fluid, and at times unpredictable, environment.
Closes: Friday 26 February 2016
PHARMAC invites proposals for the supply of seasonal influenza vaccine in New Zealand. If you wish to submit a proposal, you must submit it via the Government Electronic Tenders Service (GETS) no later than 5:00pm on 3 March 2016.
PHARMAC is pleased to announce the approval of an agreement with AstraZeneca Limited involving the listing of budesonide with eformoterol inhalers (Symbicort and Vannair).
PHARMAC is pleased to announce the approval of agreements with Boehringer Ingleheim and GlaxoSmithKline involving a number of respiratory products.
PHARMAC is seeking feedback on a proposal to list galsulfase (Naglazyme) resulting from a provisional agreement between BioMarin Pharmaceutical Australia Pty Ltd and PHARMAC. To provide feedback, please submit it in writing by 5pm on Thursday, 18 February 2016.
Proposal to list a range of Interventional Cardiology products supplied by Boston Scientific NZ Limited
PHARMAC is seeking feedback on a proposal to list a range of Interventional Cardiology products supplied by Boston Scientific NZ Limited (“Boston”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2016. The proposal is subject to approval by the PHARMAC Board or its delegate following this consultation. Please provide feedback by Friday 19 February 2016.
PHARMAC has not resolved to award any tenders for Sole Subsidised Supply Status or Hospital Supply Status this month.
PHARMAC is seeking feedback on a provisional agreement with Multichem NZ Limited, for cholecalciferol (Vit D3) 1.25 mg capsule from 1 March 2016. To provide feedback, please submit it by Wednesday, 10 February 2016.
PHARMAC is seeking feedback on a proposal to amend the listing of some respiratory products. The proposal is a result of provisional amendments to existing listing agreements with Novartis New Zealand Ltd and AstraZeneca Limited. Please submit feedback by Friday, 5 February 2016.
We are seeking a professional executive assistant who can provide effective high quality support to the Chief Executive and Board. You will also be responsible for managing a team of two Executive Assistants who support the Senior Leadership Team.
We have temporarily listed the 30 tablet pack size of Zopiclone Actavis 7.5 mg tablets, effective immediately (21 January 2016).
PHARMAC is interested in considering proposals for an IT solution able to record and manage tender bids and relevant tender bid information received during PHARMAC’s tender process (“Solution”). The Solution also needs to allow data exports to PHARMAC’s internal tender system to enable PHARMAC to analyse tender bids.
Agreement with Intermed Medical Limited for the supply of interventional cardiology, suture and wound care products
PHARMAC is pleased to announce the approval of an agreement with Intermed Medical Limited (“Intermed”) for the supply of interventional cardiology, suture and wound care products.
PHARMAC is pleased to announce that a decision has been made to award Sole Supply Status in the Community and Hospital Supply Status in DHB hospitals to Apotex NZ Limited for its Apo-Metoprolol brand of metoprolol tartrate.
You are a NZ registered medical practitioner eligible for vocational training and looking for an opportunity to advance your career.
Closes: Monday 8 February 2016.
PHARMAC is pleased to announce the approval of an agreement with Obex Medical Limited (“Obex”) for the supply of interventional cardiology products. This was the subject of a consultation letter dated 20 November 2015
PHARMAC is pleased to announce the approval of an agreement with Max Health Limited (“Max Health”) involving dexamethasone phosphate injections, used as an anti-inflammatory, glycopyrronium bromide injections, used pre-operatively and neostigmine metilsulfate with glycopyrronium bromide injections for the reversal of non-depolarising neuromuscular block. This was the subject of a consultation letter dated 23 November 2015
PHARMAC is seeking feedback on a proposal involving filgrastim and methotrexate prefilled syringes, resulting from a provisional agreement with Novartis New Zealand Ltd. This arose from an Alternative Commercial Proposal in response to consultation on the 2015/16 Invitation to Tender. Both medicines are currently listed in the Pharmaceutical Schedule. To provide feedback, please submit it in writing by Friday, 15 January 2016.